| (Nasdaq: NCEL) Makes A Swift Green Move Early Monday Behind Breaking News
*Get Our Updates Faster—Tap Here To Receive SMS Alerts*
January 12th Greetings, Friend!
NewcelX (NASDAQ: NCEL) has our full attention this morning while going green and controlling the top spot on our watchlist Monday.
Why? How about major breaking news. Check this out:
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
ZURICH, Jan. 12, 2026 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL) ("NewcelX" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solutions, today reported the results of an international collaborative research study investigating advanced biomaterial strategies to support the delivery and function of stem cell–derived islets for the treatment of Type 1 Diabetes.
The peer reviewed study, published in Diabetology, a journal dedicated to diabetes research, conducted in collaboration with research groups from the University of Technology Sydney, the University of Wisconsin–Madison, Monash University, the Queensland University of Technology, and the Australian Foundation for Diabetes Research (AFDR), examined the use of engineered scaffolds incorporating extracellular matrix (ECM) derived from a decellularized human pancreas.
The work evaluated whether ECM integration could support the function of encapsulated pluripotent stem cell–derived islets within a removable delivery system. The study results demonstrated that when ECM was incorporated into the scaffold, implanted islets exhibited functional performance comparable to encapsulated islets delivered without a scaffold. These findings suggest that biomaterial design and tissue microenvironment play a critical role in supporting islet function and may enable safer, retrievable delivery configurations for future therapeutic development.
The research was supported through a Type 1 Diabetes research initiative led by the Australian Foundation for Diabetes Research, which had received donor matched funding for the published study from the National Stem Cell Foundation of Australia. Moreover, it has received dedicated funding from Breakthrough T1D (formerly JDRF), the leading global type 1 diabetes research and advocacy organization, to further develop the underlying model based on the study results.
"This research contributes to our understanding of how advanced biomaterials and tissue microenvironments can support engineered islet function," said Prof. Michel Revel, Chief Scientific Officer of NewcelX. "The findings are consistent with the scientific principles underlying our diabetes program, which aims to combine scalable stem cell–derived islets with strategies to enhance engraftment and retrievability intended to eliminate the need for chronic immunosuppression medications."
...
Type 1 Diabetes represents NewcelX's primary therapeutic focus, and the Company is directing significant scientific and development resources toward advancing cell-based solutions in this area. The study aligns with NewcelX's scientific focus on combining stem cell biology with delivery and protection strategies to support functional insulin-producing cell therapies. IsletRx is NewcelX's investigational stem cell–derived islet therapy designed to restore insulin production in individuals with insulin-dependent diabetes. The program integrates proprietary cell differentiation protocols with immune-protective and delivery-oriented design features, with the goal of achieving functional insulin secretion without the need for systemic immunosuppression.
"Type 1 diabetes is a central focus of NewCelX's development strategy," said Ronen Twito, Executive Chairman and CEO of NewCelX. "The positive results from this international collaborative study contribute to the continued advancement of our technologies and help guide our ongoing development efforts as we move toward the clinical trial."
Read the full article here.
Remember. NCEL has a low float of roughly 2.06Mn shares. This could be important to know after today's big news.
Spend a second reviewing my initial (Nasdaq: NCEL) report below and consider this profile for your radar. -----
A major shift is underway in how scientists are approaching Type 1 Diabetes—a disease that still has no cure and affects millions worldwide. Advances in regenerative medicine are now opening the door to therapies that aim not just to manage symptoms, but to restore the body’s own ability to function, leading to actual cure.
NewcelX (NASDAQ: NCEL) has recently emerged as a unified powerhouse following a major cross-continental merger, positioning itself at the forefront of regenerative medicine and particularly on cell therapy innovation focus on Type 1 diabetes.
While many biotech companies focus on managing chronic disease, NewCelX is pursuing a more ambitious goal—replacing the insulin-producing cells destroyed by the disease, potentially allowing patients to regain natural glucose control and live independent of laborious insulin injections and glucose monitoring.
NewcelX (NASDAQ: NCEL) is a Zurich-based biotechnology firm formed through the strategic merger of NLS Pharmaceutics and Kadimastem in October 2025.
The company operates a bi-continental model with research and development headquarters in Israel, and corporate operations in Switzerland.
The Core Focus: Type 1 Diabetes
NewCelX’s lead program, IsletRx, targets Type 1 Diabetes by replacing lost insulin-producing pancreatic cells with lab-grown, clinically grade functional insulin producing cells.
Why this matters:
- Insulin injections manage symptoms, but do not cure the disease.
- Donor islet transplants prove the biology works—but donor cells are scarce and life-long immune supression treatment is needed to ensure transplanted islets survival and function.
- NewCelX’s approach aims to create an unlimited supply of insulin-producing cells, without the need for chronic immune suppression.
If successful, IsletRx could represent a functional cure rather than lifelong disease management.
A Platform Built to Scale
What differentiates NewCelX is not just a single product, but its proprietary cell-therapy platform.
The company uses human stem cells and advanced manufacturing techniques to produce high-quality, clinical-grade cells at scale—a major hurdle in cell therapy.
This platform is designed to support:
- Large-scale manufacturing
- Consistent quality
- Regulatory approval
- Strategic partnerships with larger pharmaceutical companies
Proof the Platform Works: AstroRx
While diabetes is the company’s main focus, NewCelX has already demonstrated it can execute clinically.
Its cell therapy product, AstroRx, developed for ALS, has completed Phase 1/2a clinical trials showing:
- A strong safety profile
- Encouraging signals of clinical benefit
- FDA clearance to move into a multi-site Phase 2a trial in the U.S.
Importantly, AstroRx serves as validation that NewCelX can manufacture, regulate, and advance complex cell therapies into human trials.
Recent milestones have significantly strengthened the company’s leadership and intellectual property:
Strengthened Leadership & Expertise
NewCelX has continued to build credibility through high-profile appointments:
- Dr. Julien Boisdron, a senior diabetes expert from Swiss Big Pharma (currently CMO at Roche Switzerland), joined the company’s Advisory Board in early 2026.
- This follows the November 2025 appointments of Prof. Tamir Ben-Hur and Dr. Jeremy Shefner, both globally recognized experts in neurology, to guide the company’s clinical expansion into the U.S. market.
Core Thesis: Targeting Large, Unmet Markets
Strategic Pipeline and Market Opp.
NewcelX is targeting massive, underserved markets where current standards of care offer limited relief.
NewCelX is focused on diseases where current treatments fall short:
- Type 1 Diabetes: Millions of patients, lifelong dependency on insulin
- ALS: No curative treatments, high unmet medical need
The diabetes program represents the largest value opp., with CNS programs providing validation and optional upside.
By preparing for a Phase 2a study in the U.S., NCEL is moving toward a key inflection point.
In October 2025, TargetGene Biotechnologies entered a strategic collaboration with NewCelX to develop next-generation gene-edited cell therapy for diabetes. Thus, the company aims to manufacture hypoimmune cells to evade the immune system.
Competitive Positioning & IP Protection
The company has built a strong intellectual property portfolio covering:
- Stem-cell differentiation methods
- Insulin-producing cell technologies
- Manufacturing processes
- Small-molecule neuroscience programs (DOXA)
This IP strategy helps protect NewCelX’s technology and supports future partnerships.
Financial Position and Operational Roadmap
Following the merger, NewcelX reported a strengthened balance sheet.
On a pro forma basis, the company projected shareholders' equity of approximately $20Mn as of mid-2025.
In connection with the merger, approximately $9Mn in equity financing and warrant exercises was raised to fund immediate clinical goals.
With a focus on capital-efficient development, NCEL is leveraging collaborations to extend its runway while advancing its high-value programs.
6 Potential Catalysts Send (NCEL) To The Top Of Our Watchlist Monday
#1. A Low Float:
According to info found on Yahoo Finance, NCEL has a float of approx. 2.06Mn shares. The profile may react strongly to news.
#2. Breakthrough Diabetes Data:
IsletRx is progressing toward IND-enabling studies and a first-in-human trial, supported by ongoing grants from the BIRD Foundation.
#3. FDA Clinical Entry for AstroRx:
AstroRx is preparing for a Phase 2a U.S. trial, increasing visibility
#4. Elite Scientific Advisory Board:
Academia and Big-Pharma-level expertise strengthens execution credibility.
#5. Global IP Expansion:
Patent protection across major markets supports long-term value.
#6. Manufacturing Scalability:
NewCelX has already addressed one of biotech’s biggest bottlenecks: manufacturing at scale.
Summary
NewCelX (NASDAQ: NCEL) is positioning itself as a diabetes-first cell therapy company at a time when regenerative medicine is moving from theory to reality.
With:
- A scalable cell-therapy platform
- A lead program targeting Type 1 Diabetes
- Clinical validation already achieved
- Multiple upcoming milestones
NCEL represents a compelling early-stage story in one of the most important unmet medical needs today.
All the best, Dane James Editor Market Pulse Today
Sources: NCEL Website NCEL Presentation
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
NewcelX Ltd (NCEL:US) previously changed their company name and symbols from NLS Pharmaceutics AG (NLSP:US)
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 01/11/2026 and ending on 01/12/2026 to publicly disseminate information about (NCEL:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid fourteen thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (NCEL:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ncel-jgorp/#details | 
0 التعليقات:
إرسال تعليق